anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION AND HYPOTHESIS: The objective of this study was to determine whether differences in the cumulative dietary intake of choline, is associated with the risk of developing urge urinary incontinence (UUI).
METHODS: This was an analysis within the Nurses' Health Study (NHS) I and II. The main exposure was the cumulative daily intake for each choline-containing compound obtained from a detailed daily food frequency questionnaire. The primary outcome was UUI, defined as urine loss with a sudden feeling of bladder fullness or when a toilet is inaccessible, occurring >1/month. Cox proportional hazards regression models were used to calculate multivariate-adjusted relative risks and 95% confidence intervals (CIs) for the association between total choline and choline derivatives and risk of UUI. Fixed effects meta-analyses of results from NHSI and NHSII were performed for postmenopausal women only to obtain a pooled estimate of the impact of choline consumption on UUI.
RESULTS: There were 33,273 participants in NHSI and 38,732 in NHSII who met all the criteria for inclusion in the analysis. The incidence of UUI was 9.41% (n=3,139) in NHSI and 4.25% (n=1,646) in NHSII. After adjusting for confounders choline was not found to be associated with UUI in postmenopausal women. However, in premenopausal women, relative to the lowest quartile, the highest quartile of consumption of total choline (aRR = 0.79, 95% CI: 0.64-0.99), free choline (aRR = 0.74, 95% CI: 0.58-0.94), and phosphocholine (aRR = 0.77, 95% CI: 0.61-0.96) were associated with a reduced risk of UUI.
CONCLUSIONS: Increased dietary choline consumption was associated with a reduced risk of UUI among premenopausal women.
The U.S.-affiliated Pacific Islands (USAPI) have higher cervical cancer incidence and mortality rates and lower screening coverage compared with the United States. This is likely because of economic, geographical, health care delivery, and cultural barriers for women living in these resource-constrained, isolated regions. The most recent U.S. and World Health Organization cervical cancer screening guidelines recommended primary human papillomavirus (HPV) testing as one screening option or the preferred screening modality. Primary HPV screening-based strategies offer several advantages over current screening methods in the USAPI. However, adoption of this newer screening modality has been slow in the United States and not yet incorporated into USAPI screening programs. The U.S. Centers for Disease Control and Prevention and partners initiated the Pacific Against Cervical Cancer (PACe) project in 2019 to evaluate the feasibility, acceptability, and cost-effectiveness of primary HPV testing-based strategies in Guam and in Yap, Federated States of Micronesia. This report provides an overview of the PACe project and outlines the approaches we took in implementing primary HPV testing as a new cervical cancer screening strategy (including the option of self-sampling in Yap), encompassing four core components: (1) community engagement and education, (2) medical and laboratory capacity building, (3) health information and system improvement, and (4) modeling and cost-effectiveness analysis. The PACe project provides examples of systematic implementation and resource appropriate technologies to the USAPI, with broader implications for never screened and under-screened populations in the United States and Pacific as they face similar barriers to accessing cervical cancer screening services.
The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
The present invention relates to method for assisting a user in generating an itemised medical report from at least one medical image. The at least one medical image is displayed in a display area of single computer display unit. In the same display area, a sub-region containing a checklist specific to the one or more images is displayed. Items from the checklist can be de-selected. This checklist comprises a list of selectable items, each item representing an organ, structure, or abnormality that has to be checked by the user. Linked to each item in the checklist is a default statement that is a pre-prepared statement indicative of the normality of the item. The default statement is not displayed by default as part of the checklist. The user can select an item from the checklist for providing comments by dictation thereon responsive to an observation in the radiological image. At the end of the image analysis, an editable itemised medical report is generated containing each item of the checklist as a heading and either the dictated comment or the default statement associated with the item as an observation. The editable itemised medical report is rapidly and accurately generated, information is confined to a single screen reducing the look-away time and general discomfort over time for the user.
The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
The aim of our study is to investigate the effect of neurophysiological facilitation techniques on respiratory and functional capacity in stroke individuals. The study included 68 stroke individuals hospitalized in hospital. Participants were divided into two groups as the study group (n=34) in which conventional physiotherapy and neurophysiological facilitation techniques were applied, and the control group (n=34) in which conventional physiotherapy program were applied. Demographic information of the patients was obtained, in terms of respiratory frequency, muscle strength, respiratory muscle strength, functional capacity, functional independence level, fatigue, dyspnea, comorbidity, fear of movement, mental status, pain posture, stroke impact and motor levels before and after treatment. evaluated. The neurophysiological facilitation techniques were applied 5 sessions (5-7 days) in stroke individuals. The evaluations were statistically analyzed using the SPSS(Statistical Package for the Social Sciences)-24 program. When the inspiratory muscle strengths were examined, improvement was observed in both the study and control groups, but it was noted that the muscle strength values of the study group increased significantly compared to the control group and the pre-study period (p\<0.05). When expiratory muscle strength was compared before and after treatment, improvement was observed in both groups, but there was no statistically significant difference (p\>0.05). When the functional capacity was examined, it was found that statistically significant difference was found in favor of study group (p\<0.05). In addition, when the respiratory frequency and dyspnea values of the study group were examined before and after the treatment, a statistically significant difference was found in these two values when compared to the control group (p\<0.05). No significant difference was observed in the other evaluations of the participants in both groups (p\>0.05). In conclusion, it was showed acute effect of neurophysiological facilitation techniques and it is reliable method to increase respiratory muscle strength, improve functional capacity, and decrease respiratory frequency and dyspnea levels in stroke individuals. It can be used as an alternative approach in the treatment programs to be applied to individuals with stroke and in pulmonary rehabilitation applications.
BACKGROUND: Spontaneous intracerebral hemorrhage (ICH) is a condition associated with high mortality and morbidity. Survivors may require prolonged intubation with mechanical ventilation (MV). The aim of this study was to analyze the predictors of extubation failure and prolonged MV in patients who undergo surgical evacuation.
METHODS: This retrospective study was conducted on adult patients with ICH who underwent MV for at least 48 h and survived > 14 days after surgery. The demographics, clinical characteristics, laboratory tests, and Glasgow Coma Scale score were analyzed.
RESULTS: A total of 134 patients with ICH were included in the study. The average age of the patients was 60.34 ± 15.59 years, and 79.9% (n = 107) were extubated after satisfying the weaning parameters. Extubation failure occurred in 11.2% (n = 12) and prolonged MV in 48.5% (n = 65) patients. Multivariable regression analysis revealed that a white blood cell count > 10,000/mm3 at the time of extubation was an independent predictor of reintubation. Meanwhile, age and initial Glasgow Coma Scale scores were predictors of prolonged MV.
CONCLUSIONS: This study provided the first comprehensive characterization and analysis of the predictors of extubation failure and prolonged MV in patients with ICH after surgery. Knowledge of potential predictors is essential to improve the strategies for early initiation of adequate treatment and prognosis assessment in the early stages of the disease.
The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.
Voriconazole (Vfend(Registered Trademark), Pfizer) has achieved common usage at the NIH (National Institutes of Health) Clinical Research Center for the treatment of fungal infections in immunosuppressed patients. Toxicity includes relatively frequent but reversible changes in vision and more infrequent, potentially serious hepatotoxicity, decreased cognitive function and rash. Incidence of these more serious adverse events has been difficult to ascertain because of the morbidity of underlying disease in patients receiving voriconazole, but a minimum estimate is 10 percent. It is known that voriconazole plasma concentrations vary between patients over a fifty-fold range but it is not known whether toxicity is related to plasma drug exposure. The reason for the differing voriconazole plasma concentrations between normal individuals is partly due to genetic variations in hepatic cytochrome enzymes CYP2C9 and CYP2C19 (Cytochrome P450, family 2, subfamily C, polypeptide 9 and 19, respectively). In patients with underlying illness, drug interactions and decreased hepatic drug clearance may contribute to variability.

The purpose of the study is to record prospectively the adverse effects of voriconazole in Clinical Center patients who have been prescribed the drug by their primary physician. We will ask the primary physician to order a trough voriconazole plasma levels once a week. The test will not be reported to the physician. Because interpretation of the test is unknown, the physicians will be blinded to the report. Rather, the primary objective of the study is to analyze the voriconazole plasma concentrations when the study is completed to determine if there is a concentration and duration of drug exposure that correlates with toxicity. A secondary objective is to determine the 2C9 and 2C19 genotype of patients and search for possible correlations between genotype and plasma voriconazole concentrations. Administration of other drugs given to the patient will be tracked to analyze whether any previously unknown drug interactions seem to have changed the voriconazole plasma concentration. The study will also determine the incidence of adverse effects of voriconazole in our patient population.
NEW MATERIAL:An oligomannoside of formula I (R1 and R2 are each H, acetyl or benzyl). USE:As an intermediate for the mannan with antitumor activity, and an regent for the elucidation of the biological significance of said mannan. PROCESS:First, a compound of formula II (Ac is acetyl) is made to react with benzyl alcohol in the presence of a Lewis acid catalyst followed by deacetylation to prepare a novel compound of formula III (Bn is benzyl). Secondly, this novel compound is allowed to react with the compound of the formula II mentioned above to obtain a disaccharide, which is then further made to react with a compound of formula IV (X is halogen) to produce a trisaccharide followed by deacetylation to obtain a triol trisaccharide. Thirdly, this trisaccharide is further allowed to react with a compound of formula V so that the ratio of the number of molecules of the former to the latter is 1:3 and also, if required, carriying out the protective group removal thus manufacturing the objective nonasaccharide of the formula I . Both the disaccharide and trisaccharide mentioned above are also novel compounds.
Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
The present invention mutates amino acid of a PAI-1 binding point in a TPA molecule to construct a new TPA generation mutant which has TPA activity and is not restrained by the PAI-1 on the basis that a finger-shaped area and a Kringle 1 area in the TPA molecule are removed according to the constructional characteristics of TPA. The present invention has the main content that a DNA sequence of natural TPA amino acid 1-3 and 176-527 is amplified. The PAI-1 binding point in the TPA DNA, and AAG CAC and AGG of a nucleotide sequence 373-384 are changed into GCG GCC GCG and CCG so as to mutate a corresponding amino acid KHRR into AAAA , and the new TPA mutant is constructed and cloned on a colibacillus expression vector to be expressed in colibacillus effectively. Total tropina which accounts for 30% of expression proteins exist in the form of an inclusion body. The TPA mutant with activity is obtained by the protein recoverability. The new TPA mutant is cloned on a pichia secretion type expression vector, and the TPA mutant with high activity is obtained in a cultivation supernatant. The new TPA mutant of the colibacillus and the pichia secretion type expression vector and the TPA activity are not restrained after a PAI-1 reaction is carried out, which indicates that a nucleotide sequence 373-384 and a corresponding amino acid sequence thereof influence the PAI-1 combine activity without influencing the plasminogen hydrolysis activity. Thus, the present invention relates to a novel bioengineering drug with good treating activity and less dosage for treating thrombotic diseases of myocardial infarct, cerebral thrombosis, etc. The present invention aims at a nucleotide sequence and a structure of the novel TPA mutant.
Pulmonary disease represents a substantial global health burden. Increased air pollution, especially fine particulate matter (PM2.5) is the most concerned proportion of air pollutants to respiratory health. PM2.5 may carry or combine with other toxic allergens and heavy metals, resulting in serious respiratory allergies and anaphylactic reactions in the host. Available treatment options such as antihistamines, steroids, and avoiding allergens/dust/pollutants could be limited due to certain side effects and immense exposure to air pollutants, especially in most polluted countries. In this mini-review, we summarized how PM2.5 triggers respiratory hyperresponsiveness and inflammation, and the probiotic Lactiplantibacillus plantarum supplementation could minimize the risk of the same. L. plantarum may confer beneficial effects in PM2.5-associated pulmonary inflammation due to significant antioxidant potential. We discussed L. plantarum's effect on PM2.5-induced reactive oxygen species (ROS), inflammatory cytokines, lipid peroxidation, and DNA damage. Available preclinical evidence shows L. plantarum induces gut-lung axis, SCFA, GABA, and other neurotransmitter signaling via gut microbiota modulation. SCFA signals are important in maintaining lung homeostasis and regulating intracellular defense mechanisms in alveolar cells. However, significant research is needed in this direction to contemplate L. plantarum's therapeutic potential in pulmonary allergies.
Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
Active Compatitor (Group B) will receive only stretching and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
BACKGROUND: Body weight support (BWS) training devices are frequently used to improve gait in individuals with neurological impairments, but guidance in selecting an appropriate level of BWS is limited. Here, we aim to describe the initial BWS levels used during gait training, the rationale for this selection and the clinical goals aligned with BWS training for different diagnoses.
METHOD: A systematic literature search was conducted in PubMed, Embase and Web of Science, including terms related to the population (individuals with neurological disorders), intervention (BWS training) and outcome (gait). Information on patient characteristics, type of BWS device, BWS level and training goals was extracted from the included articles.
RESULTS: Thirty-three articles were included, which described outcomes using frame-based (stationary or mobile) and unidirectional ceiling-mounted devices on four diagnoses (multiple sclerosis (MS), spinal cord injury (SCI), stroke, traumatic brain injury (TBI)). The BWS levels were highest for individuals with MS (median: 75%, IQR: 6%), followed by SCI (median: 40%, IQR: 35%), stroke (median: 30%, IQR: 4.75%) and TBI (median: 15%, IQR: 0%). The included studies reported eleven different training goals. Reported BWS levels ranged between 30 and 75% for most of the training goals, without a clear relationship between BWS level, diagnosis, training goal and rationale for BWS selection. Training goals were achieved in all included studies.
CONCLUSION: Initial BWS levels differ considerably between studies included in this review. The underlying rationale for these differences was not clearly motivated in the included studies. Variation in study designs and populations does not allow to draw a conclusion on the effectiveness of BWS levels. Hence, it remains difficult to formulate guidelines on optimal BWS settings for different diagnoses, BWS devices and training goals. Further efforts are required to establish clinical guidelines and to experimentally investigate which initial BWS levels are optimal for specific diagnoses and training goals.
The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
World Health Organization suggests that ideally cesarean section rate should not be more than 10% to 15%. The investigators should focus to reduce rate of primary cesarean section as well as repeat cesarean with cephalic presentation and singleton pregnancy after previous 1 cesarean section. Therefore, all ladies who underwent previous 1 cesarean section for non-recurrent cause should be considered for vaginal birth. Though studies show that membrane sweeping does promote the onset of labor and avoid need for formal induction of labor for prolonged pregnancy but the effects of membrane sweeping in women with a prior cesarean delivery are largely unknown. It is reported in literature that there is no significant increase risk to maternal or neonatal outcome with membrane sweeping. The rationale of the study was to compare the effect of membrane sweeping with no sweeping in the successful onset of labor in patients with one previous Cesarean Section so that the investigators can reduce the cesarean section rate. Objective of the study was to determine the effect of membrane sweeping on the onset of labor, success of vaginal delivery and neonatal outcome in patients with previous one cesarean section.
PROBLEM TO BE SOLVED: To provide a novel schizophrenia therapeutic drug which can reduce the side effects caused by antipsychotic drugs while maintaining the efficacy, by reducing dosage of combined antipsychotic drugs.SOLUTION: The invention provides a medicament for the treatment of schizophrenia characterized by administering a compound represented by general formula (I) in combination with at least one kind of antipsychotic drug. [Ris a C1-C3 alkyl group, etc.; Ris a C1-C3 alkoxy C1-C3 alkyl group, etc.; Ris C1-C6 alkyl group, etc.; Rand Rare, each independently, a C1-C6 alkyl group which may be substituted by a hydrogen atom, a hydroxy group, etc., or an (azetidine-1-yl) carbonyl group which may be substituted by a hydroxy group etc.; and at least one of Rand the Ris a hydrogen atom.]SELECTED DRAWING: None